Needs StatementThis two part educational series is meant to build clinician knowledge and competence about the best practice for managing Type II Diabetes as related to prescribing non-insulin as well as insulin therapies. These utility driven modules are designed to provide tips and algorithms that the primary care clinician can use in the clinic right away. These modules have been developed as part of the BMC Portfolio Program's Performance Improvement CME activity on Diabetes Management, but has been made available as a public resource.
- Part 1 - Non-insulin Therapies
- Part 2 - Insulin
According to the Center for Disease Control and Prevention (CDC), the diabetes epidemic continues to rise among the United States population. An individual with diabetes has twofold the risk of death compared to someone without diabetes. Diabetes can lead to kidney failure, non-traumatic lower-limb amputations, and new cases of blindness among adults. Diabetes is also a major cause of heart disease and stroke. Approximately 95% of all diagnosed cases of diabetes in adults are type 2 diabetes (T2DM).* Recent guideline changes and newly available therapies have made it ever more challenging for the PCP to confidently assist their patients in staying ahead of disease progression.[i] Clinical inertia and uncertainty lead to poor glycemic control.**
*Centers for Disease Control and Prevention. Diabetes Report Card 2012. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2012. Available at: www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf. Accessed June 20, 2016.
**Inzucchi, SE, Bergenstal, RM, Buse, JB, Diamant, Ferrannini, E, Nauck, M, Peters, A, Tsapas, A, Wender, R, Matthews, D Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach - Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35 (6): 1364-1379.
Target AudiencePhysicians, physician assistants, NPs, and other allied healthcare professionals.
ObjectivesPart 1-Using Non-insulin Agents
At the completion of this module the learner will:
- Identify the 12 classes of diabetes medications
- Explain how non-insulin agents address the main pathophysiologic defects of T2DM
- Recognize the benefits and risks of the newer non-insulin agents for T2DM: DPP-4 inhibitors, GLP-1 RAs and SGLT-2 inhibitors
- Apply knowledge of metabolic staging of T2DM to initiate and advance therapy, particularly with the newer non-insulin agents
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Accreditation Provider Number: 0000185
- Patient care
- Medical knowledge
- Provide patient-centered care
- Employ evidence-based practice
Faculty DisclosureBoston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Elliot Sternthal, MD, FACP, FACE
Dr. Sternthal has no relevant financial relationships to disclose.
Faculty member does not plan to discuss unlabeled/investigational uses of a commercial product.
Jason Worcester, MD
Emma Trucks, MPH
Emily Jansen, MPH
Members of the planning committee have no relevant financial relationships to disclose.